Blog

Company News

Industry Trends

Laws Regulations

All Categories >

22

2024-09

Statement on the Label Change for Hycells’s New Product

Dear Sir/Madam, We would like to express our heartfelt gratitude for your organization’s unwavering support and trust in Hycells over the years.

2024-09-22

He Yousheng

18

2024-09

Good News | Hycells Awarded the Title of “Shanghai Specialized, Refined, Distinctive, and Innovative SME” for 2024

2024年9月6日， 上海市经济和信息化委员会发布了《2024年上海市专精特新中小企业名单(第二批)》公示名单，上海合佑生生物科技有限公司也非常荣幸位列其中。

2024-09-18

He Yousheng

10

2024-09

Minhang District Talent Bureau and Hycells Build a “Concentric Circle” of Industry-Talent Services

Talent is the “primary resource” for enterprises. To attract and retain top talent, Shanghai has introduced a series of policies on household registration for high-caliber professionals, thereby empowering corporate development. This year, with the establishment of talent service bureaus in each district of Shanghai, the “green channel” between talent service agencies and businesses has been further streamlined. Through mechanisms such as policy-driven entry into industrial parks, tailored guidance for scaling up operations, and direct on-site services for enterprises, the city has continuously refined its proactive service delivery model, deploying a coordinated package of door-to-door support initiatives to build a concentric “circle” of industry–talent services.

2024-09-10

He Yousheng

26

2024-08

Disease Sample Services | Compliance-Focused Collection Services for Autoimmune Disease Samples Empower the Hundreds-of-Billion-Dollar Autoimmune Market

Autoimmune diseases (AIDs) are immune dysregulatory disorders in which the body’s normal autoimmune homeostasis is disrupted, leading to aberrant immune responses against self-cell or tissue antigens and, consequently, damage to or dysfunction of autologous tissues. AIDs affect 5% to 8% of the global population, imposing substantial suffering on patients; their incidence may even surpass that of cardiovascular disease and cancer, making them a leading cause of mortality worldwide.

2024-08-26

He Yousheng

18

2024-07

Pujiang’s “Golden Butler” Supports Enterprise Growth, Blossoming Along the Way

Recently, Ms. Qi from the Human Resources Department of Shanghai Hycells Biotechnology Co., Ltd. visited the Pujiang Town Community Affairs Service Center and presented a banner inscribed with “Dedicated and Responsible, Always Caring for the People; Alleviating Worries and Solving Problems, Serving Enterprises” to the center, in gratitude for the “Golden Butler” team’s assistance in handling enterprise-related matters such as points-based household registration and entrepreneurship subsidies.

2024-07-18

He Yousheng

09

2024-07

Europharm, Hycells Biotechnology, and Beike Pharmaceutical Have Entered into a Strategic Partnership in the Field of RCL Testing

In July 2024, Europharm Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Europharm”), Shanghai Hycells Biotechnology Co., Ltd. (hereinafter referred to as “Hycells Bio”), and Beike (Beijing) Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as “Beike Pharma”) entered into a strategic cooperation agreement. The three parties jointly announced that they will engage in in-depth collaboration in areas such as biosafety testing involving P3 laboratories—including replicable lentivirus (RCL) assays and mycobacterial verification—for CGT products, as well as immunogenicity studies for peptide products. Leveraging their respective strengths and expertise in biopharmaceutical testing, the three parties will work together to provide end-to-end, one-stop services to biopharmaceutical clients, thereby achieving mutual benefit and win-win outcomes.

2024-07-09

He Yousheng
< 1...111213...24 >